Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.
Opsonophagocytic activity (OPA) was measured following reduced infant doses of 7-valent pneumococcal conjugate vaccine (PCV-7) with or without 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months, and subsequent re-exposure to a small dose of pneumococcal polysaccharide antigens (mPPS) at 17 months. Fijian infants were randomized to receive 0, 1, 2, or 3 PCV-7 doses. Half received PPV-23 at 12 months and all received mPPS at 17 months. OPA was performed on up to 14 serotypes. Three and 2 PCV-7 doses resulted in similar OPA for most PCV-7 serotypes up to 9 months and for half of the serotypes at 12 months. A single dose improved OPA compared with the unvaccinated group. PPV-23 significantly improved OPA for all serotypes tested but in general, was associated with diminished responses following re-challenge.
Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Australia. fmruss@unimelb.edu.au
F M
FM
Russell
J R
JR
Carapetis
R L
RL
Burton
J
J
Lin
P V
PV
Licciardi
A
A
Balloch
L
L
Tikoduadua
L
L
Waqatakirewa
Y B
YB
Cheung
M L K
ML
Tang
M H
MH
Nahm
E K
EK
Mulholland
D000907:Antibodies, Bacterial / Q000097:blood*; D005367:Fiji; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007223:Infant; D009895:Opsonin Proteins / Q000097:blood*; D010587:Phagocytosis / Q000276:immunology*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D009895:Opsonin Proteins; D022242:Pneumococcal Vaccines